Micell raises $62m for MiStent SES

Micell Technologies said last week that it raised a debt-and-equity round worth nearly $62 million from a syndicate of 51 unnamed investors.

Paris-based Micell makes the MiStent SES sirolimus-eluting absorbable polymer coronary stent, designed to treat coronary artery disease. The company, which reported a nearly $26 million round last November, said in a regulatory filing that the funding involved debt, equity and preferred return notes.

Get the full story on our sister site, Drug Delivery Business News.

The post Micell raises $62m for MiStent SES appeared first on MassDevice.

from MassDevice http://ift.tt/2jFq5ro